A clinical trial of GT90008 for the treatment of advanced solid tumours
Latest Information Update: 27 Oct 2021
At a glance
- Drugs GT 90008 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Suzhou Kintor Pharmaceuticals
- 27 Oct 2021 New trial record
- 21 Oct 2021 According to a Kintor Pharma media release, the company received approval from the National Medical Products Administration (NMPA) of China on 21 October 2021 for the clinical trial of PD-L1/TGF-beta dual-targeting antibody (GT90008) for the treatment of advanced solid tumours.